Arno Therapeutics, Inc. announced that it has expanded its management team with the appointments of Joseph Bisaha, PhD as Vice President, Clinical Operations and Project Management and David M. Jackson, PhD as Vice President, Diagnostics. These additions to the company's team of highly experienced and skilled members are expected to support the continued clinical development of Arno's lead compound and personalized therapy onapristone and the co-development of a companion diagnostic and other biomarkers with various partners and collaborators. Dr. Bisaha will be responsible for the planning, implementation and daily operations of Arno's drug development projects, including the ongoing clinical trials of onapristone, for which the Company anticipates to soon enroll the first patient in a Phase I dose escalation study.

Dr. Jackson will manage various biomarker and companion diagnostic (CDx) co-development partnerships in support of onapristone. Prior to his appointment as Vice President, Clinical Operations and Project Management, Dr. Bisaha was a Clinical Research Consultant with Kaizen Clinical Services Inc, where he was responsible for Arno's Clinical Operations and Project Management activities. Dr. Jackson joins Arno Therapeutics as Vice President, Diagnostics.

Prior to joining Arno, he was Vice President, Business Development at PrimeraDx, Inc.